Project Grant R01CA299152
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$449K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $695,004 to The University of Texas MD Anderson Cancer Center to conduct research on improving therapies for non-small cell lung cancer patients with HER2-activating mutations. The key objectives are to: 1) Comprehensively characterize the landscape of HER2 mutations associated with response or resistance to HER2-targeted tyrosine kinase inhibitors...
The University of Texas Southwestern Medical Center (UT Southwestern) received a $642,429 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to study acquired cross-resistance in small cell lung cancer (SCLC). The funding will support research using a panel of 72 patient-derived xenograft models to investigate how genetic alterations, specifically extrachromosomal amplification of MYC family genes, drive resistance to both standard chemotherapies...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $224,100 to Vanderbilt University to conduct research on "Understanding Biased Agonism in Receptor Tyrosine Kinases to Devise New Modalities for Their Targeting in Cancer." The project aims to directly observe the kinetics of receptor tyrosine kinase (RTK) signaling in living cells, with a focus on the epidermal growth factor receptor (EGFR) and its different activating...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $191,675 to The University of Texas Southwestern Medical Center to conduct research on the role of Jumonji demethylases in small cell lung cancer (SCLC) and their potential as drug targets. The research aims to investigate whether inhibiting these epigenetic enzymes can block SCLC growth and overcome therapeutic resistance, including in chemotherapy-resistant disease models....
This federal Project Grant award of $491,826.00 was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The University of Texas Southwestern Medical Center to investigate the role of the testis-specific serine kinase 6 (TSSK6) in colorectal cancer. The research aims to comprehensively examine how TSSK6 influences focal adhesion formation and signaling, as well as its impact on tumor metastasis, viability, and chemoresistance in mouse and organoid models. This...
This $802,230 R21 project grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to study mechanisms underlying the resistance of breast cancer brain metastases (BCBM) to RET inhibitor drugs. The research will determine the role of the TGLI1 gene in conferring BCBM resistance to RET monotherapy, and evaluate if dual targeting of RET and TGLI1 can synergistically inhibit BCBM. The award was provided to the University of Texas Health Science Center at...
The National Cancer Institute (NCI) awarded a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Institute For Cancer Research, a non-profit affiliate of Temple University. The grant supports research to investigate the use of an aromatase inhibitor (AI) in combination with anti-PD1 immunotherapy as a novel treatment approach for non-small cell lung cancer (NSCLC) patients with EGFR mutations. The research will involve studies in mouse models of...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.398 - Cancer Research Manpower program provides $270,981 in funding to The University of Texas Southwestern Medical Center in Dallas, TX from August 2025 to July 2030. The grant supports research to define mechanisms of immunotherapy resistance and target the TIGIT immune checkpoint in hepatobiliary cancers such as hepatocellular carcinoma and biliary tract cancers. Key objectives include conducting a Phase 2 clinical...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $279,465 to the University of Colorado-Denver to support research aimed at understanding how the tumor microenvironment impacts response to tyrosine kinase inhibitor (TKI) therapies in patients with ALK-positive non-small cell lung cancer (NSCLC). The key focus is determining how neutrophils recruited to the tumor microenvironment impair anti-tumor CD8+ T cell activity and...
This $544,475 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and validation of a novel in vitro cancer metastasis model system using decellularized organ tissues, or "biomatrices." The primary objectives are to:
Generate a comprehensive panel of biomatrices representing common sites of cancer metastasis (e.g. liver, lung) to recapitulate organ-specific tumor biology and treatment response.
Demonstrate the...